Yinan Lin was recently quoted in a BioWorld article, "China’s IITs the ‘buzzword of the year’.”

Yinan Lin was recently quoted in a BioWorld article, “China’s IITs the ‘buzzword of the year’,” which discusses how China’s investigator-initiated trial (IIT) regime has made the country a go-to destination for early-stage clinical trials. These trials also allow companies to eliminate weak candidates early, before investing significant time and capital in a product that may fail. “[In regards to IIT Trial Regime] Conducted in a few patients, such trials can provide the early data a company needs to attract investors,” said Yinan. To read more, click here.